# Co-infection with Pseudomonas aeruginosa and Mycobacterium avium complex in patients with bronchiectasis: coincidence or inevitability?

## TL;DR

This paper explores whether co-infection with Pseudomonas aeruginosa and Mycobacterium avium complex in bronchiectasis patients is a coincidence or a common occurrence, and how it affects disease severity.

## Contribution

The paper provides a comprehensive review of the epidemiology and mechanisms of co-infection with M. avium complex and P. aeruginosa in bronchiectasis.

## Key findings

- M. avium complex and P. aeruginosa coexist in bronchiectasis patients with one pathogen dominating at a time.
- Coinfection leads to higher disease burden compared to infection with either pathogen alone.
- The interactions between these pathogens remain poorly understood, complicating treatment strategies.

## Abstract

The burden of bronchiectasis is rapidly escalating worldwide, with its airway microbiome shifting from a “single-pathogen” paradigm to “multiple-pathogen coexistence.” Both Mycobacterium avium complex and Pseudomonas aeruginosa infections have been demonstrated to exacerbate airway destruction, yet they are rarely examined concurrently. Emerging evidence suggests these pathogens exhibit a long-term coexistence pattern within the same patient, with one dominating when the other recedes. Furthermore, existing studies indicate that the disease burden in coinfected patients is higher than in those with either pathogen alone. However, the specific competitive and synergistic interactions between M. avium complex and P. aeruginosa in bronchiectasis patients remain poorly recognized, posing substantial therapeutic challenges. This review summarizes current understanding of the epidemiology and clinical manifestations of M. avium complex and P. aeruginosa co-infection in patients with bronchiectasis, along with potential mechanisms of microbial interaction between the two pathogens.